+

WO1992002216A1 - Inhibiteurs de glycolysation avancee renfermant des acides et des derives amino-benzoiques, et methodes d'utilisation - Google Patents

Inhibiteurs de glycolysation avancee renfermant des acides et des derives amino-benzoiques, et methodes d'utilisation Download PDF

Info

Publication number
WO1992002216A1
WO1992002216A1 PCT/US1991/005457 US9105457W WO9202216A1 WO 1992002216 A1 WO1992002216 A1 WO 1992002216A1 US 9105457 W US9105457 W US 9105457W WO 9202216 A1 WO9202216 A1 WO 9202216A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amino
group
composition
formula
Prior art date
Application number
PCT/US1991/005457
Other languages
English (en)
Other versions
WO1992002216A2 (fr
Inventor
Peter C Ulrich
Anthony Cerami
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/561,066 external-priority patent/US5137916A/en
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of WO1992002216A1 publication Critical patent/WO1992002216A1/fr
Publication of WO1992002216A2 publication Critical patent/WO1992002216A2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à des compositions et à des procédés d'inhibition de la réticulation non enzymatique (vieillissement protéique). On décrit donc une composition comprenant un agent capable d'inhiber la formation de produits finaux de glycosylation avancée de protéines cibles par réaction avec la portion carbonyle du produit de glycosylation précoce de telles protéines cibles formé par leur glycosylation initiale. Le procédé comprend la mise en contact de la protéine cible avec la composition. On envisage des applications industrielles et thérapeutiques de l'invention étant donné que l'on peut prévenir la détérioration des aliments et le vieillissement des protides d'origine animale.
PCT/US1991/005457 1990-08-01 1991-08-01 Inhibiteurs de glycolysation avancee renfermant des acides et des derives amino-benzoiques, et methodes d'utilisation WO1992002216A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US561,066 1990-08-01
US07/561,066 US5137916A (en) 1985-11-14 1990-08-01 Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use

Publications (2)

Publication Number Publication Date
WO1992002216A1 true WO1992002216A1 (fr) 1992-02-20
WO1992002216A2 WO1992002216A2 (fr) 1992-02-20

Family

ID=

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586806A1 (fr) * 1992-07-13 1994-03-16 Hoechst Aktiengesellschaft Utilisation de dérivés du 2-(N-(2-Aminoethyl)amino)acide acétique dans le traitement des maladies liées à la glycosylation non-enzymatique
EP0604641A1 (fr) * 1992-06-30 1994-07-06 SHAPIRO, Howard, K. Composition contenant des derives amines ou apparentes aux amines d'acide benzoique et utilisations, y compris dans le traitement de maladies inflammatoires
WO1996040622A1 (fr) * 1995-06-07 1996-12-19 Alteon Inc. Bis-(2-aryl)hydrazones inhibiteurs de la formation de produits finaux de glycosylation avancee
WO1997009981A1 (fr) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
WO1998043649A3 (fr) * 1997-03-28 1998-12-17 Otsuka Pharma Co Ltd Composition inhibant la production de produits terminaux de glycosylation avancee comprenant un inhibiteur de la reaction de maillard et la vitamine b¿6?
WO1999025690A2 (fr) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Intermediaires de produits terminaux de glycosylation avancee et inhibition post-amadori
WO1999059536A1 (fr) * 1998-05-15 1999-11-25 Unilever Plc Utilisation d'un agent de prevention des gingivites
WO2000023063A3 (fr) * 1998-10-22 2000-07-13 Univ South Carolina Procedes pour inhiber les complications diabetiques
WO2000021516A3 (fr) * 1998-10-14 2001-01-04 Kansas University Medical Ct R Procedes destines a empecher des complications diabetiques
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812554A (en) * 1905-11-08 1906-02-13 Hoechst Ag Alkamin esters of para-aminobenzoic acid.
GB1197083A (en) * 1963-12-12 1970-07-01 Mar Sal Inc Treatment of Arteriosclerotic, Atherosclerotic and Related Metabolic Diseases
GB1256235A (en) * 1966-06-20 1971-12-08 Rumanian Minister Of The Food Cream for the care and regeneration of the skin
DE2914935A1 (de) * 1978-04-20 1979-10-31 Sandoz Ag Antidiabetische verwendung von anthranilsaeurederivaten
DE3023433A1 (de) * 1979-06-25 1981-01-08 May & Baker Ltd Acylaminobenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
EP0068407A1 (fr) * 1981-06-22 1983-01-05 Hodogaya Chemical Co., Ltd. Dérivés d'acide aminosulfonylebenzoique
EP0222313A2 (fr) * 1985-11-14 1987-05-20 The Rockefeller University Procédé et remèdes pour l'inhibition du vieillissement des protéines
EP0316852A2 (fr) * 1987-11-13 1989-05-24 The Rockefeller University Inhibiteurs du croisement non enzymatique
EP0450598A2 (fr) * 1990-04-03 1991-10-09 The Rockefeller University Des inhibiteurs de la glycosylation avancée des protéines, et méthodes pour leur utilisation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812554A (en) * 1905-11-08 1906-02-13 Hoechst Ag Alkamin esters of para-aminobenzoic acid.
GB1197083A (en) * 1963-12-12 1970-07-01 Mar Sal Inc Treatment of Arteriosclerotic, Atherosclerotic and Related Metabolic Diseases
GB1256235A (en) * 1966-06-20 1971-12-08 Rumanian Minister Of The Food Cream for the care and regeneration of the skin
DE2914935A1 (de) * 1978-04-20 1979-10-31 Sandoz Ag Antidiabetische verwendung von anthranilsaeurederivaten
DE3023433A1 (de) * 1979-06-25 1981-01-08 May & Baker Ltd Acylaminobenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
EP0068407A1 (fr) * 1981-06-22 1983-01-05 Hodogaya Chemical Co., Ltd. Dérivés d'acide aminosulfonylebenzoique
EP0222313A2 (fr) * 1985-11-14 1987-05-20 The Rockefeller University Procédé et remèdes pour l'inhibition du vieillissement des protéines
EP0316852A2 (fr) * 1987-11-13 1989-05-24 The Rockefeller University Inhibiteurs du croisement non enzymatique
EP0450598A2 (fr) * 1990-04-03 1991-10-09 The Rockefeller University Des inhibiteurs de la glycosylation avancée des protéines, et méthodes pour leur utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STN International, File CA, Chemical Abstracts, volume 108, no. 1, 4 January 1988, (Columbus, Ohio, US), I. Madar et al: "Glucose uptake and conversion into glycogen in isolated diabetic rat aorta under the influence of procaine, Aslavital and Gerovital H3", abstract 602w, & Rev. Roum. Biol.; Ser.Biol. Anim.; 32(1), 43-7, 1987 *
STN International, File CA, Chemical Abstracts, volume 79, no. 3, 23 July 1973, (Columbus, Ohio, US), M. Mihailescu: "Therapeu- tical value of glutamic acid and procaine in the evolution of some metabolic changes in alloxan diabetes", abstract 13515c, & Fiziol. Norm. Patol., 18(3), 275-83, 1972 *
The Merck Index, an encyclopedia of chemicals, drugs, and biologicals, eleventh edition,1989 Susan Budavari et al., see page 69, no. 434; page 72-73, no. 454; page 1230-1231, no. 7763 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604641A1 (fr) * 1992-06-30 1994-07-06 SHAPIRO, Howard, K. Composition contenant des derives amines ou apparentes aux amines d'acide benzoique et utilisations, y compris dans le traitement de maladies inflammatoires
EP0604641A4 (fr) * 1992-06-30 1995-08-02 Howard K Shapiro Composition contenant des derives amines ou apparentes aux amines d'acide benzoique et utilisations, y compris dans le traitement de maladies inflammatoires.
EP0586806A1 (fr) * 1992-07-13 1994-03-16 Hoechst Aktiengesellschaft Utilisation de dérivés du 2-(N-(2-Aminoethyl)amino)acide acétique dans le traitement des maladies liées à la glycosylation non-enzymatique
WO1996040622A1 (fr) * 1995-06-07 1996-12-19 Alteon Inc. Bis-(2-aryl)hydrazones inhibiteurs de la formation de produits finaux de glycosylation avancee
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6472400B1 (en) 1995-09-12 2002-10-29 University Of Kansas Medical Center Advanced gylcation end-product intermediaries and post-Amadori inhibition
WO1997009981A1 (fr) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6472411B1 (en) 1995-09-12 2002-10-29 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
WO1998043649A3 (fr) * 1997-03-28 1998-12-17 Otsuka Pharma Co Ltd Composition inhibant la production de produits terminaux de glycosylation avancee comprenant un inhibiteur de la reaction de maillard et la vitamine b¿6?
WO1999025690A3 (fr) * 1997-11-17 1999-07-22 Univ Kansas Medical Center Intermediaires de produits terminaux de glycosylation avancee et inhibition post-amadori
WO1999025690A2 (fr) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Intermediaires de produits terminaux de glycosylation avancee et inhibition post-amadori
US6290975B1 (en) 1998-05-15 2001-09-18 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method for the prevention of gum disease
WO1999059536A1 (fr) * 1998-05-15 1999-11-25 Unilever Plc Utilisation d'un agent de prevention des gingivites
WO2000021516A3 (fr) * 1998-10-14 2001-01-04 Kansas University Medical Ct R Procedes destines a empecher des complications diabetiques
WO2000023063A3 (fr) * 1998-10-22 2000-07-13 Univ South Carolina Procedes pour inhiber les complications diabetiques

Also Published As

Publication number Publication date
AU8449591A (en) 1992-03-02

Similar Documents

Publication Publication Date Title
US5130337A (en) Amidrazones and derivatives thereof
US5100919A (en) Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5130324A (en) 2-alkylidene-aminoguanidines and methods of use therefor
US5272165A (en) 2-alkylidene-aminoguanidines and methods of use therefor
US5334617A (en) Amino acids useful as inhibitors of the advanced glycosylation of proteins
US5272176A (en) Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5106877A (en) Aminoalcohol compounds in methods of use as inhibitors of the advanced glycosylation of proteins and methods of use therefor
USRE38330E1 (en) Preventing and reversing advanced glycosylation endproducts
US5358960A (en) Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles
US5218001A (en) Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US5221683A (en) Diaminopyridine compounds and methods of use
US5137916A (en) Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5262152A (en) Amidrazones and derivatives thereof
US5114943A (en) Amino-substituted pyrimidines, derivatives and methods of use therefor
US5258381A (en) 2-substituted-2-imidazolines
US5852009A (en) Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US5318982A (en) Inhibition of the advanced glycosylation of proteins using substituted-1,2,4-triazoles
US5500439A (en) Aminopyrazoles
US5698563A (en) Bis- hydrazones!
US5661139A (en) Bis-(2-aryl) hydrazones
US5326779A (en) Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles
US5243071A (en) 2-alkylidene-aminoguanidines and methods of use therefor
US5254593A (en) Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
US5534540A (en) Methods of inhibiting the advanced glycosylation of proteins using tetramic and tetronic acids and compositions therefor
US5612332A (en) Di- and triaminoguanidines, and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载